Abstract
The present study intends to develop an in-situ forming gel (ISFG) vehicle for the sustained and gradual delivery of risperidone to schizophrenic patients for longer drug dosing intervals. Initial burst release (IBR) was evaluated for the lipid liquid crystals (LLCs) containing glycerol monooleate (GMO), glycerol dioleate (GDO), and glycerol trioleate (GTO), along with different percentages of phosphatidylcholine (PC) as the oil phase, and N-methyl-2-pyrrolidone (NMP) as the solvent. In vitro evaluations, pharmacokinetics, and histopathological studies in rabbits were done to find the optimal LLC formulation. The formulation containing GDO had lower IBR in comparison with the other formulations, including Risperdal CONSTA®. Microscopy assessment indicated that the structures of LLC formulations containing GMO, GDO, and GTO cubic (Q2) were hexagonal (HII) and an intermediate form of HII and Q2, respectively. Comparison of the pharmacokinetic data showed that the optimal LLC containing GDO/PC with the ratio of 2.2:1 and 30% NMP created more consistent release profiles in vitro and in vivo during 60 days. Histopathology results in rabbits showed almost no side effects for the formulations. This study emphasized the better drug delivery potential of GDO-based gel-forming systems compared to Risperdal CONSTA®, which would increase patient compliance and decrease the inconvenience of frequent drug oral administrations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
